Market capitalization | $86.06b |
Enterprise Value | $105.45b |
P/E (TTM) P/E ratio | 13.53 |
EV/FCF (TTM) EV/FCF | 121.06 |
EV/Sales (TTM) EV/Sales | 0.61 |
P/S ratio (TTM) P/S ratio | 0.49 |
P/B ratio (TTM) P/B ratio | 1.97 |
Dividend yield | 1.76% |
Last dividend (FY24) | $6.52 |
As a Free StocksGuide user, you can view scores for all 6,886 stocks worldwide.
24 Analysts have issued a Elevance Health forecast:
24 Analysts have issued a Elevance Health forecast:
Sep '24 |
+/-
%
|
||
Revenue | 174,015 174,015 |
3%
3%
|
|
Gross Profit | - - |
-
|
|
EBITDA | - - |
-
|
EBIT (Operating Income) EBIT | 9,202 9,202 |
3%
3%
|
Net Profit | 6,418 6,418 |
6%
6%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Elevance Health, Inc. operates as a health company, which engages in improving lives and communities, and making healthcare simpler. It operates through the following segments: Commercial and Specialty Business, Government Business, CarelonRx, and Other. The Commercial and Specialty Business segment provides insurance products and services such as stop loss, dental, vision, life, disability and supplemental health insurance. The Government Business segment includes medicare and medicaid businesses, national government services, and services provided to the federal government. The CerelonRx segment offers formulary management, pharmacy networks, prescription drug database, member services, and mail order capabilities. The Other segment is involved in health services business focused on quality of healthcare by enabling and creating new care delivery and payment models. The company was founded in 1944 and is headquartered in Indianapolis, IN.
Head office | United States |
CEO | Gail Boudreaux |
Employees | 104,900 |
Founded | 1944 |
Website | www.elevancehealth.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.